Medication-Induced Hair Loss: The Common Prescriptions That Shed Hair

Drug-induced hair loss is the most frequently overlooked cause of non-AGA hair shedding. Identifying the causative agent requires timeline awareness and knowledge of which drug classes are most commonly implicated.

Drug-induced alopecia is underdiagnosed because the two-to-four-month lag between starting a medication and observing hair loss makes the causal connection non-obvious. A patient who started a new medication in month one and notices shedding in month three or four rarely makes the connection without clinical guidance.

Mechanisms of drug-induced hair loss

Two primary mechanisms produce medication-induced hair loss:

Telogen effluvium: The medication interrupts anagen maintenance, pushing a cohort of follicles into premature telogen. The TE mechanism is shared by many drugs and produces diffuse shedding 2–4 months after the triggering event. The follicles themselves are not permanently damaged; recovery occurs if the drug is discontinued or the dose reduced.

Anagen effluvium: Drugs that directly inhibit rapidly dividing cells (particularly chemotherapy agents targeting mitosis) damage matrix cells during the growth phase, producing rapid hair loss without the 2–4 month lag. Anagen effluvium may be dramatic and rapid (significant hair loss within weeks), reflecting the direct disruption of active follicle production rather than TE's delayed shed of already-resting follicles.

High-risk drug classes

Anticoagulants: Heparin (including LMWH), warfarin, and direct oral anticoagulants have all been associated with TE. The mechanism is incompletely understood but may involve effects on follicle vascularisation or direct interference with the fibrin-based extracellular matrix of the follicle.

Retinoids: Isotretinoin (Accutane) commonly causes TE, particularly at higher doses. The effect is dose-dependent and typically reversible on discontinuation. Retinoids modulate retinoic acid signalling in follicle cells, accelerating catagen.

Beta-blockers: Particularly propranolol, atenolol, and metoprolol have case reports and case series of TE. The mechanism is uncertain; reduced scalp perfusion (from peripheral vasoconstriction) has been proposed.

Testosterone replacement therapy: Exogenous testosterone in men with AGA-susceptible follicles increases substrate for DHT conversion, potentially accelerating AGA. This is distinct from TE and represents a worsening of the underlying androgen-driven miniaturisation process rather than medication TE.

Clinical approach

When evaluating new-onset diffuse hair shedding: systematically review all medications started in the preceding six months. The Naranjo algorithm for drug causality assessment provides a structured approach. Do not discontinue essential medications without physician discussion — the prescribing team can assess alternatives, dose adjustments, or adjunctive treatments (minoxidil to support anagen re-entry during TE from a necessary drug).